Supplemental Table S1. Sample cross-validation table: reports of cross-hallmark effects of selected metabolic approaches Resveratrol Metformin pyruvate (DCA) (3PB) - (PFK15) sulfide (GW5074) (BPTES) Acid (FX11) Dysregulated Metabolism Approaches Other cancer hallmarks (TEPP-46) + + + + Genomic Instability 0 0 0 0 0 [4] [5] [1] [2, 3] [6] + + +/- + +/- + + + 0 0 [25] [26] [27] Sustained Proliferative Signaling [7-9] [10-20] [21] [4] [22-24] + + + + Tumor Promoting Inflammation 0 0 0 0 0 0 [31] [28] [29, 30] [32] + + + + + + + Evasion of Anti-growth Signalling 0 0 0 [38] [33, 34] [26, 39] [35, 36] [37] [4] [27] + + + + + Resistance to Cell 0 0 0 0 0 [41] [25] [40] [36] [4] + + Replicative Immortality 0 0 0 0 0 0 0 0 [42, 43] [12, 44, 45] +/- + + Immune System Evasion 0 0 0 0 0 0 0 [32, 52] [46-49] [50, 51]
Supplemental Table S1. Sample cross-validation table: reports of cross-hallmark effects of selected metabolic approaches Dysregulated Metabolism Approaches Other cancer hallmarks Resveratrol Metformin (3PB) (PFK15) (TEPP-46) (DCA) (GW5074) sulfide (BPTES) Acid (FX11) Genomic Instability + [1] + [2, 3] 0 + [4] 0 0 + [5] 0 0 - [6] Sustained Proliferative Signaling + [7-9] +/- [10-20] + [21] + [4] 0 + [22-24] + [25] +/- [26] + [27] 0 Tumor Promoting Inflammation + [28] + [29, 30] 0 0 + [31] + [32] 0 0 0 0 Evasion of Anti-growth Signalling + [33, 34] + [35, 36] + [37] + [4] 0 0 + [38] + [26, 39] + [27] 0 Resistance to Cell + [40] + [36] + [41] + [4] 0 0 + [25] 0 0 0 Replicative Immortality + [42, 43] + [12, 44, 45] 0 0 0 0 0 0 0 0 Immune System Evasion +/- [46-49] + [50, 51] 0 0 0 + [32, 52] 0 0 0 0 pyruvate
1-s2.0-S1044579X15000887-mmc1.docx